Shin Nippon Biomedical Laboratories, Ltd.
1. First Half Results for the Fiscal Year Ending March 2027
First-half results: net sales 17.56 hundred million yen, operating income 1.55 hundred million yen, ordinary income 3.08 hundred million yen, net income attributable to owners of parent 2.19 hundred million yen. Achieved significant year-over-year revenue and profit growth. Order timing shifts in CRO non-clinical and cost timing adjustments in the TR business were contributing factors. Full-year FY2027 forecast was also raised, indicating improved utilization in research-related businesses and progress on new projects.
Key Figures
- Net Sales First Half 17.56 hundred million yen (FY2026 First Half actual)
- Operating Income First Half 1.55 hundred million yen
- Ordinary Income First Half 3.08 hundred million yen
- Net Income Attributable to Owners of Parent First Half 2.19 hundred million yen
- FY2027 Full-Year Forecast Includes First Half Results
AI要約
Overview of Results
The first-half results for the fiscal year ending March 2027 showed net sales of 17.56 hundred million yen (YoY +19.0%), operating income of 1.55 hundred million yen, ordinary income of 3.08 hundred million yen, and net income attributable to owners of parent of 2.19 hundred million yen, representing substantial improvement. Increased orders and sales in both non-clinical and clinical CRO businesses and the deferral of TR business expenses to the second half contributed to profit improvement. Equity in earnings from affiliates such as Shin Nippon Biomedical Laboratories PPD also contributed.
Outlook and Impact for Investors
The full-year FY2027 forecast is expected to be revised upward as contributing factors persist. Growth in the CRO business is anticipated due to stronger orders from clients in Europe and the U.S., and expansion of the TR business including Atzumi is expected to progress. Although some expense deferral to the second half may continue, overall the company plans to strengthen its long-term growth foundation through allocation of capital expenditures and R&D spending.
Segment Revenue Breakdown
Shin Nippon Biomedical Laboratories, Ltd.
Company overview · Stock price · Financial data · All IR
